Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 8/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | USP2 | O75604 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 2/20 | 0.37 |
| ▸ | HBB | P68871 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 6/20 | 0.37 |
| ▸ | RAB9A | P51151 | 6/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL90933 | 0.84 | MMP12 (0.36) | MMP12MAPTALDH1A1GAAHSD17B10 | |
| SCHEMBL15761051 | 0.83 | — | — | |
| SCHEMBL8281886 | 0.82 | MAPT (0.44) | MMP12MAPTALDH1A1GAAHSD17B10 | |
| SCHEMBL12748562 | 0.81 | ALDH1A1 (0.40) | MMP12MAPTALDH1A1GAAHSD17B10 | |
| SCHEMBL9518303 | 0.76 | BLM (0.46) | MAPTMEN1KMT2ANPC1RAB9A | |
| SCHEMBL31152587 | 0.76 | AHR (0.40) | MAPTGAAKDM4EMEN1KMT2A | |
| SCHEMBL30792604 | 0.76 | CYP3A4 (0.55) | MAPTALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL8022331 | 0.76 | CA1 (0.38) | ALDH1A1GAAHSD17B10KDM4EMEN1 | |
| SCHEMBL1167973 | 0.76 | LMNA (0.51) | MAPTALDH1A1GAAHSD17B10KDM4E | |
| SCHEMBL7007389 | 0.76 | ALOX5 (0.33) | MAPTALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3875151-B1 | ALPHA-METHYL-SUBSTITUTED DIAZABICYCLO [4.3.1] DECANE DERIVATES FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2023-09-20 | — | — | EP | disclosed |
| EP-4159736-A1 | NOVEL TRICYCLIC AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Longwood Biopharmaceuticals Co., Ltd. (CN) | 2023-04-05 | — | — | EP | disclosed |
| EP-3875151-A1 | ALPHA-METHYL-SUBSTITUTED DIAZABICYCLO [4.3.1] DECANE DERIVATES FOR TREATMENT OF PSYCHIATRIC DISORDERS | Technische Universität Darmstadt (DE) | 2021-09-08 | — | — | EP | disclosed |
| EP-2714032-B1 | NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS | GREEN CROSS CORP (KR) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017217792-A1 | METHOD FOR PRODUCING DIPHENYLMETHANE DERIVATIVE | 주식회사 대웅제약 | 2017-12-21 | — | — | WO | disclosed |
| EP-3097103-B1 | DIAZABICYCLO[4.3.1]DECANE DERIVATIVES FOR TREATMENT OF PSYCHIATRIC DISORDERS | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WSS (DE) | 2017-11-15 | — | — | EP | disclosed |
| EP-3012250-B1 | ISOQUINOLINE MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMA (US) | 2017-11-08 | — | — | EP | disclosed |
| EP-3208272-A1 | HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | Vertex Pharmaceuticals Incorporated (US) | 2017-08-23 | — | — | EP | disclosed |
| EP-3191484-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND THEIR USE IN THERAPY | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) | 2017-07-19 | — | — | EP | disclosed |
| US-20170107206-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-04-20 | — | — | US | disclosed |
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | DUMAS JACQUES | 2010-03-25 | — | — | US | disclosed |
| WO-2010025235-A1 | SELECTIVE LIGANDS FOR THE DOPAMINE 3 (D3) RECEPTOR AND METHODS OF USING THE SAME | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20090233923-A1 | PYRIDO-PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233923-A1 | PYRIDO-PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | US | disclosed |
| US-7544682-B2 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-06-09 | — | — | US | disclosed |
| US-7544682-B2 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2009-06-09 | — | — | US | disclosed |
| US-20080015199-A1 | Triazolone derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| EP-1636585-B1 | DIARYL UREAS WITH KINASE INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| US-20070167469-A1 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | US | disclosed |
| US-20070167469-A1 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167469-A1 | Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof | DPYD, PNPO, TYMP | MMP12 4830/4885MAPT 2111/4885ALDH1A1 407/4885 |
| US-20100075971-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISORDERS | CDK4, MKI67, TP53 | MMP12 4427/4885MAPT 1522/4885ALDH1A1 1298/4885 |
| US-20090233923-A1 | PYRIDO-PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | DPYD, PNPO, TYMP | MMP12 4824/4885MAPT 1950/4885ALDH1A1 470/4885 |
| US-20170107206-A1 | MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS | CFTR, ABCB1, ABCC2 | MMP12 2682/4885MAPT 4509/4885ALDH1A1 1786/4885 |
| US-20080015199-A1 | Triazolone derivatives | F3, F12, F2 | MMP12 2390/4885MAPT 3959/4885ALDH1A1 710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.